Adrenal gland – Adrenocortical adenoma showing moderate intensity cytoplasmic CTLA-4 immunostaining. This occurs in most adrenal gland tumors. Given the good performance of the antibody on lymphocytes and the fact, that other commercial anti-CTLA-4 antibodies also have substantial other issues, this represents a (tolerable) cross-reactivity.
Adrenal gland - Adrenocortical adenoma showing moderate intensity cytoplasmic CTLA-4 immunostaining. This occurs in most adrenal gland tumors. Given the good performance of the antibody on lymphocytes and the fact, that other commercial anti-CTLA-4 antibodies also have substantial other issues, this represents a (tolerable) cross-reactivity.
Colon- Colorectal adenocarcinoma containing few CTLA-4 positive lymphocytes. A weak CTLA-4 staining of the basal cell membrane is also seen in a fraction of cells. This represents a (tolerable) cross-reactivity.
Colon- Colorectal adenocarcinoma containing few CTLA-4 positive lymphocytes. A weak CTLA-4 staining of the basal cell membrane is also seen in a fraction of cells. This represents a (tolerable) cross-reactivity. 
Colon- Colorectal adenocarcinoma containing many CTLA-4 positive lymphocytes.
Colon- Colorectal adenocarcinoma containing many CTLA-4 positive lymphocytes.
Colon- Colorectal adenocarcinoma showing CTLA-4 immunostaining in a significant fraction of tumor infiltrating lymphocytes.
Colon- Colorectal adenocarcinoma showing CTLA-4 immunostaining in a significant fraction of tumor infiltrating lymphocytes. 
Kidney – Clear cell renal cell carcinoma showing moderate to strong cytoplasmic CTLA-4 immunostaining. This occurs in a small fraction of kidney tumors. Given the good performance of the antibody on lymphocytes and the fact, that other commercial anti-CTLA-4 antibodies also have substantial other issues, this represents a (tolerable) cross-reactivity.
Kidney - Clear cell renal cell carcinoma showing moderate to strong cytoplasmic CTLA-4 immunostaining. This occurs in a small fraction of kidney tumors. Given the good performance of the antibody on lymphocytes and the fact, that other commercial anti-CTLA-4 antibodies also have substantial other issues, this represents a (tolerable) cross-reactivity.
Kidney- Clear cell renal cell carcinoma lacking CTLA-4 positive tumor infiltrating lymphocytes.
Kidney- Clear cell renal cell carcinoma lacking CTLA-4 positive tumor infiltrating lymphocytes. 
Lymph node- Angioimmunoblastic T-cell lymphoma containing numerous CTLA-4 positive lymphocytes.
Lymph node- Angioimmunoblastic T-cell lymphoma containing numerous CTLA-4 positive lymphocytes. 
Lymph node- Diffuse large B-cell lymphoma displaying a large number of CTLA-4 positive lymphocytes.
Lymph node- Diffuse large B-cell lymphoma displaying a large number of CTLA-4 positive lymphocytes.
Lymph node- Diffuse large B-cell lymphoma containing many reactive CTLA-4 positive lymphocytes.
Lymph node- Diffuse large B-cell lymphoma containing many reactive CTLA-4 positive lymphocytes. 
Lymph node- Follicular B-cell lymphoma containing a large number of CTLA-4 positive lymphocytes.
Lymph node- Follicular B-cell lymphoma containing a large number of CTLA-4 positive lymphocytes. 
Lymph node- Hodgkin’s lymphoma containing numerous reactive CTLA-4 positive lymphocytes.
Lymph node- Hodgkin’s lymphoma containing numerous reactive CTLA-4 positive lymphocytes. 
Lymph node- Hodgkin’s lymphoma including numerous reactive CTLA-4 positive lymphocytes.
Lymph node- Hodgkin’s lymphoma including numerous reactive CTLA-4 positive lymphocytes. 
Oral cavity- A significant fraction of tumor infiltrating lymphocytes shows CTLA-4 immunostaining in a squamous cell carcinoma.
Oral cavity- A significant fraction of tumor infiltrating lymphocytes shows CTLA-4 immunostaining in a squamous cell carcinoma. 
Oral cavity- Squamous cell carcinoma containing few CTLA-4 positive lymphocytes. A CTLA-4 staining is also seen in some maturing carcinoma cells. This represents a (tolerable) cross-reactivity.
Oral cavity- Squamous cell carcinoma containing few CTLA-4 positive lymphocytes. A CTLA-4 staining is also seen in some maturing carcinoma cells. This represents a (tolerable) cross-reactivity. 
Parotid gland- Warthin tumor containing numerous CTLA-4 positive lymphocytes.
Parotid gland- Warthin tumor containing numerous CTLA-4 positive lymphocytes. 
Penis- Squamous cell carcinoma containing numerous CTLA-4 positive lymphocytes.
Penis- Squamous cell carcinoma containing numerous CTLA-4 positive lymphocytes. 
Prostate- CTLA-4 positive lymphocytes are absent in a prostatic adenocarcinoma (Gleason 3+3=6).
Prostate- CTLA-4 positive lymphocytes are absent in a prostatic adenocarcinoma (Gleason 3+3=6). 
Prostate- Only few CTLA-4 positive lymphocytes are seen in a prostatic adenocarcinoma (Gleason 5+4=9).
Prostate- Only few CTLA-4 positive lymphocytes are seen in a prostatic adenocarcinoma (Gleason 5+4=9). 
Stomach- CTLA-4 positive lymphocytes are absent in a gastrointestinal stromal tumor (GIST).
Stomach- CTLA-4 positive lymphocytes are absent in a gastrointestinal stromal tumor (GIST). 
Testis- A significant fraction of tumor infiltrating lymphocytes shows CTLA-4 immunostaining in a seminoma.
Testis- A significant fraction of tumor infiltrating lymphocytes shows CTLA-4 immunostaining in a seminoma. 
Testis- Few CTLA-4 positive tumor infiltrating lymphocytes are seen in a seminoma.
Testis- Few CTLA-4 positive tumor infiltrating lymphocytes are seen in a seminoma. 
Thyroid- Only few CTLA-4 positive lymphocytes are seen in a papillary carcinoma.
Thyroid- Only few CTLA-4 positive lymphocytes are seen in a papillary carcinoma. 
Vulva- A significant number of CTLA-4 positive lymphocytes is seen in a squamous cell carcinoma.
Vulva- A significant number of CTLA-4 positive lymphocytes is seen in a squamous cell carcinoma.